Sinovac Biotech Ltd., a China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply its inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) to the pediatric population in Jiangsu Province. Sinovac is one of two selected manufacturers, and will supply 900,000 doses of Healive to Jiangsu province. The total volume includes as many as 1.8 million doses.   Healive is the first inactivated...